Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Hansa Announces Global Pivotal Phase 3 Trial in Anti-GBM Disease
Hansa Biopharma, a pioneer in enzyme technology for rare immunological conditions, today announced the first […]
Hansa Biopharma Completes Enrollment in Phase 2 Study of Imlifidase in Guillain-Barré Syndrome (GBS)
Hansa Biopharma, a pioneer in enzyme technology for rare immunological conditions, today announced it has […]
Hansa Biopharma Announces Positive Reimbursement in Spain for Idefirix as Desensitization Treatment for Patients in Kidney Transplantation
Hansa Biopharma, a pioneer in enzyme technology for rare immunological conditions, has announced that the […]
Matthew Shaulis appointed Chief Commercial Officer and US President of Hansa Biopharma
Hansa Biopharma, a pioneer in enzyme technology for rare immunological conditions, announced today that Matthew […]
NICE Recommends Use of Hansa Biopharma's Idefirix® (Imlifidase) as Desensitization Treatment for Highly Sensitized Kidney Transplant Patients
Hansa Biopharma, “Hansa” (Nasdaq Stockholm: HNSA), pioneer in enzyme technology for rare immunological conditions, today […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more